Roche Inks Potential $1B AAV Vector Deal with Avista for Eye Disease
Pittsburgh-based Avista Therapeutics has inked a partnership deal with Swiss pharma company Roche to develop AAV gene therapy vectors for eye diseases. The collaboration will use Avista’s single-cell adeno-associated virus (AAV) engineering platform, scAAVengr, to...
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin
Adhera Therapeutics, Inc. (OTCQB: ATRX), a clinical stage biopharmaceutical company, announces that the Company has entered a Heads of Terms (also known as a Letter of Intent) agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin, a novel...
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced a two-year sponsored research agreement with Sunnybrook Research Institute (SRI) to expedite the identification of novel drug candidates that inhibit Bax and Bak with high potency, specificity, and appropriate...
Omega Gets FDA Nod to Start First-Ever Epigenomic Controller Trial
Development-stage biotech company Omega Therapeutics announced Thursday that the Investigational New Drug (IND) application for its hepatocellular carcinoma (HCC) candidate, OTX-2002, has received clearance from the U.S. Food and Drug Administration. This clearance...
Regeneron, Sanofi Look to Extend Dupixent into Young Kids with Eosinophilic Esophagitis
In the latest win for Regeneron Pharmaceuticals and Sanofi's Dupixent (dupilumab), the partners announced positive results from a Phase III trial of the blockbuster in kids ages one to 11 years with eosinophilic esophagitis (EoE). Dupixent has been approved globally...
Light at the End of Long Road as FDA Greenlights Novavax Vaccine
The U.S. Food and Drug Administration granted Novavax’s COVID-19 vaccine Emergency Use Authorization (EUA) after a lengthy and obstacle-riddled journey. It is authorized as a two-dose primary series for adults 18 years and older. On June 7, the FDA’s Vaccines and...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com